RxDoctor Payments Data

Mark Strauss, MD

Internal Medicine · Corpus Christi, TXNPI 1629053186

Payments from drug & device makers

$1,120in general payments, 2019–2025

Across 88 payments — averaging $12.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$213
  • Pfizer$131
  • Kowa Pharmaceuticals America, Inc.$111
  • Merck$85
  • Johnson & Johnson$75
  • Radius Health, Inc.$61
  • plus $445 from 13 others

What the payments were for

  • Food & beverage$1,06095%
  • Education$595%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,120 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$213,942
Medicare patients
388
Services billed
13,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$86,166
XareltoRivaroxaban69$76,953
MounjaroTirzepatide71$70,972
JanuviaSitagliptin Phosphate39$55,468
EliquisApixaban43$49,458
JardianceEmpagliflozin31$39,874
Tresiba Flextouch U-200Insulin Degludec16$29,945
ProliaDenosumab16$27,252
JanumetSitagliptin Phos/Metformin Hcl22$24,818
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$22,527
Dexlansoprazole DrDexlansoprazole40$15,745
Atorvastatin Calcium922$9,381
Valsartan346$9,338
Advair HfaFluticasone Propion/Salmeterol18$8,861
Nebivolol Hcl174$8,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$54$86,16685 claims
MerckJanuvia, Janumet$85$80,28661 claims
Johnson & JohnsonXarelto$75$76,95369 claims
Lilly USA, LLCMounjaro$213$70,97271 claims
PfizerEliquis$131$49,45843 claims
AmgenProlia$27$27,25216 claims
AstraZenecaSymbicort$58$3,97116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →